title: Assessment of biological effectiveness of boron neutron capture therapy in primary and metastatic melanoma cell lines.
abstract: OBJECTIVE
  In order to optimize the effectiveness of Boron Neutron Capture Therapy (BNCT), Relative Biological Effectiveness (RBE) and Compound Biological Effectiveness (CBE) were determined in two human melanoma cell lines, M8 and Mel-J cells, using the amino acid p-boronophenylalanine (BPA) as boron carrier.
  
  
  METHODS
  The effects of BNCT on the primary amelanotic cell line M8 and on the metastatic pigmented melanoma cell line Mel-J were studied using colony formation assay. The RBE values were determined using both a gamma ray source, and the neutron beam from the Nuclear Reactor of the National Atomic Energy Commission (RA-3). For the determination of the RBE, cells were irradiated with increasing doses of both sources, between 1 and 8 Gy; and for the determination of CBE factors, the cells were pre-incubated with BPA before irradiation. Afterwards, the cell surviving fraction (SF) was determined for each treatment.
  
  
  RESULTS
  Marked differences were observed between both cell lines. Mel-J cells were more radioresistant than the M8 cell line. The clonogenic assays showed that for a SF of 1%, the RBE values were 1.3 for M8 cells and 1.5 for Mel-J cells. Similarly, the CBE values for a 1% SF were 2.1 for M8 and 3 for Mel-J cell lines. For the endpoint of 0.1% of SF the RBE values obtained were 1.2 for M8 and 1.4 for Mel-J cells. Finally, CBE values calculated for a 0.1% were 2 and 2.6 for M8 and Mel-J cell lines respectively. In order to estimate the uptake of the non-radioactive isotope Boron 10 ((10)B), a neutron induced autoradiographic technique was performed showing discrepancies in (10)B uptake between both cell lines.
  
  
  CONCLUSIONS
  These obtained in vitro results are the first effectiveness factors determined for human melanoma at the RA-3 nuclear reactor and show that BNCT dosimetry planning for patients could be successfully performed using these new factors.
authors.affiliation: Nuclear Regulatory Authority (ARN) , Argentina.
authors.forename: Andrés E
authors.initials: AE
authors.lastname: Rossini
authors.forename: Maria A
authors.initials: MA
authors.lastname: Dagrosa
authors.forename: Agustina
authors.initials: A
authors.lastname: Portu
authors.forename: Giselle
authors.initials: G
authors.lastname: Saint Martin
authors.forename: Silvia
authors.initials: S
authors.lastname: Thorp
authors.forename: Mariana
authors.initials: M
authors.lastname: Casal
authors.forename: Aimé
authors.initials: A
authors.lastname: Navarro
authors.forename: Guillermo J
authors.initials: GJ
authors.lastname: Juvenal
authors.forename: Mario A
authors.initials: MA
authors.lastname: Pisarev
mesh_terms: D001345:Autoradiography; D001692:Biological Transport / Q000528:radiation effects; D001896:Boron Compounds / Q000378:metabolism; D016754:Boron Neutron Capture Therapy; D045744:Cell Line, Tumor; D006801:Humans; D042541:Intracellular Space / Q000378:metabolism / Q000528:radiation effects; D008545:Melanoma / Q000473:pathology*; D009362:Neoplasm Metastasis; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000378:metabolism; D011836:Radiation Tolerance; D012062:Relative Biological Effectiveness
chemical_list: D001896:Boron Compounds; D010649:Phenylalanine; C033685:4-boronophenylalanine
keywords: Boron Neutron Capture Therapy (BNCT); Compound Biological Effectiveness (CBE); Relative Biological Effectiveness (RBE); borophenylalanine; melanoma